Mitochondria are the energy producers in cells, and MOTS-C helps them work more efficiently
Thus a 70 kg (150 lbs) person would be given around 110 g a day in hypothetical future research trials involving BPC-157 as an oral supplement
At the same time, the decisive factor remains individual assessment the stage of the disease, general condition, and therapeutic goals always require a personalized approach
patients can resume normal activities immediately
however, there are important compatibility considerations when mixing it with other drugs
A phase 1 clinical trial was conducted to evaluate the safety and pharmacokinetics of BPC 157 compared to placebo in healthy volunteers, with results reportedly submitted to ClinicalTrials.gov on May 23, 2016